Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy
Advanced Science · 2026
DOI: 10.1002/advs.202522025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yuce Lu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences …. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Precision Medicine, Bile Duct Neoplasms, Printing, Three-Dimensional. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy with a dismal prognosis, and pronounced interpatient heterogeneity severely limits the efficacy of systemic therapies, underscoring the need for rapid and accurate functional platforms to guide individualized drug selection. Here, we develop a clinically oriented, patient‐derived, 3D bioprinted in vitro model for personalized drug sensitivity assessment in ICC. Using a compositionally defined and cost‐effective GelMA/HAMA composite hydrogel, we reconstruct a tumor microenvironment that supports rapid self‐organization and sustained viability of primary ICC cells. Histological analyses, marker expression profiling, and bright‐field imaging demonstrate close similarity to matched patient tumor tissues. Genomic and transcriptomic fidelity are further confirmed by whole‐exome and RNA sequencing, revealing preserved driver mutations and transcriptional programs. Drug sensitivity testing was performed on tumor samples from 21 ICC patients using clinically relevant agents. Notably, in patients receiving neoadjuvant therapy, in vitro drug responses were fully consistent with clinical outcomes. Longitudinal follow‐up further showed that recurrence occurred exclusively in patients who did not receive the predicted sensitive therapies. Importantly, clinically actionable drug response profiles were generated within 10 days. Collectively, this platform provides a rapid, reproducible, and patient‐specific functional drug testing strategy with strong potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences (CAMS), Beijing, China.
- Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, P.R. China.
ORCID-Profile: Yilei Mao
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Lu, Y., Du, L., Sun, M., Zhang, K., Pang, M., Jiang, S., Dong, J., Liu, X., Jin, B., Xu, F., Sun, H., Zhang, J., Yang, H., Yang, X., Lu, X., Xu, Y., Zhao, H., Du, S., Sang, X., …, & Mao, Y. (2026). Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy. Advanced Science. https://doi.org/10.1002/advs.202522025
Vancouver
Lu Y, Du L, Sun M, Zhang K, Pang M, Jiang S, et al. Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy. Advanced Science. 2026. doi:10.1002/advs.202522025
BibTeX
@article{Lu2026,
author = {Lu, Yuce and Du, Liwei and Sun, Minghao and Zhang, Kai and Pang, Mingchang and Jiang, Shangze and Dong, Jiaxun and Liu, Xiyue and Jin, Bao and Xu, Fu and Sun, Hang and Zhang, Jiangang and Yang, Huiyu and Yang, Xiaobo and Lu, Xin and Xu, Yiyao and Zhao, Haitao and Du, Shunda and Sang, Xinting and Zheng, Yongchang and Zhang, Lei and Wan, Xueshuai and Yang, Huayu and Mao, Yilei},
title = {Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202522025}
}
EUVIMED